Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPTNASDAQ:SAGENASDAQ:SCPHNASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPTOpthea$3.41+7.2%$4.30$1.79▼$6.30$524.84M1.1226,131 shs3,000 shsSAGESage Therapeutics$6.86-6.9%$7.53$4.62▼$17.05$421.76M0.481.24 million shs3.92 million shsSCPHscPharmaceuticals$2.32+0.9%$3.15$2.20▼$5.65$116.66M0.38341,958 shs570,812 shsURGNUroGen Pharma$10.25-2.7%$10.72$9.03▼$20.70$472.46M0.8505,988 shs523,746 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPTOpthea0.00%0.00%-3.94%-9.31%-13.67%SAGESage Therapeutics-5.15%-14.90%+0.68%+20.03%-57.03%SCPHscPharmaceuticals-8.00%-24.34%-30.09%-35.93%-55.85%URGNUroGen Pharma-5.98%-8.03%+9.69%-6.07%-22.91%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPTOpthea0.8217 of 5 stars2.11.00.00.02.20.80.6SAGESage Therapeutics3.5895 of 5 stars3.02.00.04.01.31.71.3SCPHscPharmaceuticals3.3924 of 5 stars3.52.00.04.20.01.70.6URGNUroGen Pharma3.094 of 5 stars3.60.00.04.50.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPTOpthea 2.17Hold$1.33-60.90% DownsideSAGESage Therapeutics 2.00Hold$8.8128.46% UpsideSCPHscPharmaceuticals 3.00Buy$14.00503.45% UpsideURGNUroGen Pharma 3.17Buy$38.20272.68% UpsideCurrent Analyst Ratings BreakdownLatest SCPH, OPT, URGN, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/20/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $12.003/20/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.003/11/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $55.003/10/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/3/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09SAGESage Therapeutics$41.24M10.23N/AN/A$7.56 per share0.91SCPHscPharmaceuticals$36.33M3.21N/AN/A$1.04 per share2.23URGNUroGen Pharma$90.40M5.23N/AN/A($2.78) per share-3.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/ASAGESage Therapeutics-$400.67M-$6.59N/AN/AN/A-971.50%-68.18%-60.84%4/24/2025 (Estimated)SCPHscPharmaceuticals-$54.81M-$1.90N/AN/AN/A-264.60%-244.93%-68.56%5/13/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.23N/AN/AN/A-129.11%N/A-47.94%5/12/2025 (Estimated)Latest SCPH, OPT, URGN, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025N/ASAGESage Therapeutics-$1.00N/AN/AN/A$14.12 millionN/A3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 million3/10/2025Q4 2024URGNUroGen Pharma-$0.69-$0.80-$0.11-$0.80$25.25 million$24.57 million2/11/2025Q4 2024SAGESage Therapeutics-$1.54-$1.56-$0.02-$1.56$14.37 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPTOptheaN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPTOptheaN/A2.942.94SAGESage TherapeuticsN/A7.427.42SCPHscPharmaceuticals1.668.086.89URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPTOpthea55.95%SAGESage Therapeutics99.22%SCPHscPharmaceuticals89.52%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipOPTOpthea3.20%SAGESage Therapeutics5.50%SCPHscPharmaceuticals5.52%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPTOpthea8153.91 million148.98 millionNot OptionableSAGESage Therapeutics69061.48 million58.10 millionOptionableSCPHscPharmaceuticals3050.28 million47.28 millionOptionableURGNUroGen Pharma20046.09 million22.26 millionOptionableSCPH, OPT, URGN, and SAGE HeadlinesRecent News About These CompaniesUroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% - Here's WhyApril 4 at 11:44 AM | marketbeat.comRosalind Advisors Inc. Makes New $9.27 Million Investment in UroGen Pharma Ltd. (NASDAQ:URGN)March 23, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock Price Up 3.6% - Time to Buy?March 21, 2025 | marketbeat.comPrivium Fund Management B.V. Purchases Shares of 27,691 UroGen Pharma Ltd. (NASDAQ:URGN)March 20, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of "Buy" from AnalystsMarch 16, 2025 | marketbeat.comHC Wainwright Reduces Earnings Estimates for UroGen PharmaMarch 14, 2025 | marketbeat.comHC Wainwright Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $55.00March 12, 2025 | marketbeat.com34,701 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Purchased by Bender Robert & AssociatesMarch 12, 2025 | marketbeat.comUroGen Pharma price target lowered to $55 from $64 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comUroGen Pharma sees FY25 operating expenses $215M-$225MMarch 10, 2025 | markets.businessinsider.comUrogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch targetMarch 10, 2025 | msn.comUroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comUroGen Pharma's (URGN) "Buy" Rating Reiterated at D. Boral CapitalMarch 10, 2025 | marketbeat.comUrogen Pharma (URGN) Reports Q4 Loss, Lags Revenue EstimatesMarch 10, 2025 | zacks.comUroGen Pharma (NASDAQ:URGN) Issues Quarterly Earnings ResultsMarch 10, 2025 | marketbeat.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comUroGen Pharma (URGN) to Release Earnings on ThursdayMarch 6, 2025 | marketbeat.comUroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025February 27, 2025 | businesswire.comIs UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?February 26, 2025 | insidermonkey.comUroGen Pharma to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel Stock Surges on New CEO – The Real Story Runs DeeperBy Gabriel Osorio-Mazilli | March 13, 2025View Intel Stock Surges on New CEO – The Real Story Runs DeeperSuper Micro Stock: $7.2M Call Options Signal Big Upside PotentialBy Gabriel Osorio-Mazilli | March 24, 2025View Super Micro Stock: $7.2M Call Options Signal Big Upside Potential3 Stocks to Buy While Others Stay on the SidelinesBy Chris Markoch | March 8, 2025View 3 Stocks to Buy While Others Stay on the SidelinesModerna: 4 Key Reasons the CEO Just Bought $5M in SharesBy Jea Yu | March 11, 2025View Moderna: 4 Key Reasons the CEO Just Bought $5M in SharesIntel's Strategy to Win the Next AI FrontierBy Jeffrey Neal Johnson | March 27, 2025View Intel's Strategy to Win the Next AI FrontierSCPH, OPT, URGN, and SAGE Company DescriptionsOpthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 04/3/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Sage Therapeutics NASDAQ:SAGE$6.86 -0.51 (-6.92%) Closing price 04:00 PM EasternExtended Trading$6.62 -0.24 (-3.56%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.scPharmaceuticals NASDAQ:SCPH$2.32 +0.02 (+0.87%) Closing price 04:00 PM EasternExtended Trading$2.32 0.00 (0.00%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.UroGen Pharma NASDAQ:URGN$10.25 -0.28 (-2.66%) Closing price 04:00 PM EasternExtended Trading$10.27 +0.02 (+0.20%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
